InMode (NASDAQ:INMD) Sets New 1-Year Low – Here’s What Happened

InMode Ltd. (NASDAQ:INMD)’s stock price reached a new 52-week low on Monday . The company traded as low as $12.95 and last traded at $12.9830, with a volume of 502175 shares changing hands. The stock had previously closed at $13.23.

Analyst Ratings Changes

A number of analysts have recently issued reports on INMD shares. Canaccord Genuity Group set a $15.00 target price on InMode and gave the stock a “hold” rating in a research report on Wednesday, December 17th. BTIG Research reissued a “neutral” rating on shares of InMode in a report on Monday, January 26th. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a research note on Thursday, January 22nd. Finally, Robert W. Baird set a $17.00 target price on InMode in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.80.

InMode Trading Down 2.1%

The company has a market cap of $820.83 million, a P/E ratio of 9.00 and a beta of 2.18. The company’s 50-day moving average price is $14.56 and its two-hundred day moving average price is $14.68.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.42 by $0.04. The business had revenue of $103.85 million for the quarter, compared to analysts’ expectations of $104.64 million. InMode had a net margin of 25.33% and a return on equity of 14.52%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.42 earnings per share. As a group, analysts anticipate that InMode Ltd. will post 1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Deutsche Bank AG increased its holdings in shares of InMode by 35.9% in the 4th quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company’s stock worth $58,000 after acquiring an additional 1,037 shares during the period. Quadrant Capital Group LLC grew its position in InMode by 127.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after purchasing an additional 1,091 shares during the last quarter. Aviva PLC increased its stake in shares of InMode by 3.9% in the second quarter. Aviva PLC now owns 33,264 shares of the healthcare company’s stock valued at $480,000 after purchasing an additional 1,263 shares during the period. Blue Trust Inc. increased its stake in shares of InMode by 93.7% in the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock valued at $43,000 after purchasing an additional 1,384 shares during the period. Finally, Leonteq Securities AG bought a new stake in shares of InMode during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.